Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder

Neuroscience

Volumn 316, Issue , 2016, Pages 209-220

  Cobb, J A ^a   O'Neill, K ^a   Milner, J ^a   Mahajan, G J ^a   Lawrence, T J ^a   May, W L ^b   Miguel Hidalgo, J ^a   Rajkowska, G ^a   Stockmeier, C A ^a,c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Astrocyte; GFAP; Hippocampus; Major depressive disorder; Postmortem

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN;

ADULT; ARTICLE; ASTROCYTE; BRAIN TISSUE; CAUSAL ATTRIBUTION; CAUSE OF DEATH; CELL DENSITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DENTATE GYRUS; DISEASE DURATION; FEMALE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA2 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR DEPRESSION; MALE; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE; ADOLESCENT; AGE; AGED; HEMISPHERIC DOMINANCE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PHYSIOLOGY; POSTMORTEM CHANGE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ASTROCYTES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FUNCTIONAL LATERALITY; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; POSTMORTEM CHANGES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84953326424     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.12.044     Document Type: Article

References (87)

1. Amaral D., Lavenex P. Hippocampal neuroanatomy. The hippocampus book 2007, 37-114. Oxford University Press, New York. P. Andersen, R. Morris, D. Amaral, T. Bliss, J. O'Keefe (Eds.).
2. American Psychiatric Association (APA) Diagnostic and statistical manual of mental disorders 1994, APA, Washington, DC. 4th ed.
3. Araya-Callís C., Hiemke C., Abumaria N., Flugge G. Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus. Psychopharmacology 2012, 224:209-222.
4. Bachis A., Mallei A., Cruz M.I., Wellstein A., Mocchetti I. Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology 2008, 55:1114-1120.
5. Banasr M., Duman R.S. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008, 64:863-870.
6. Bremner J.D., Narayan M., Anderson E.R., Staib L.H., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. Am J Psychiatry 2000, 157:115-118.
7. Brown E.S., Hughes C.W., McColl R., Peshock R., King K.S., Rush A.J. Association of depressive symptoms with hippocampal volume in 1936 adults. Neuropsychopharmacology 2014, 3:770-779.
8. Carter B.S., Hamilton D.E., Thompson R.C. Acute and chronic glucocorticoid treatments regulate astrocyte-enriched mRNAs in multiple brain regions in vivo. Front Neurosci 2013, 7:1-14.
9. Chandley M.J., Szebeni K., Szebeni A., Crawford J., Stockmeier C.A., Turecki G., Miguel-Hidalgo J.J., Ordway G.A. Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder. J Psychiatry Neurosci 2013, 38:276-284.
10. Chen J.X., Yao L.H., Xu B.B., Qian K., Wang H.L., Liu Z.C., Wang X.P., Wang G.H. Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress. J Huazhong Univ Sci Technolog Med Sci 2014, 34:838-844.
11. Cobb J.A., Simpson J., Mahajan G., Overholser J.C., Jurjus G.J., Dieter L., Herbst N., May W., Rajkowska G., Stockmeier C.A. Hippocampal volume and total cell numbers in major depressive disorder. J Psychiatr Res 2013, 47:299-306.
12. Cyranowski J.M., Frank E., Young E., Shear M.K. Adolescent onset of the gender difference in lifetime rates of major depression: a theoretical model. Arch Gen Psychiatry 2000, 57:21-27.
13. Czéh B., Simon M., Schmelting B., Hiemke C., Fuchs E. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006, 31:1616-1626.
14. Czéh B., Di Benedetto B. Antidepressants act directly on astrocytes: evidences and functional consequences. Eur Neuropsychopharmacol 2013, 23:171-185.
15. DeJong T.M., Overholser J.C. Assessment of depression and suicidal actions: agreement between suicide attempters and informant reports. Suicide Life Threat Behav 2009, 39:38-46.
16. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
17. Duric V., Banasr M., Licznerski P., Schmidt H.D., Stockmeier C.A., Simen A.A., Newton S.S., Duman R.S. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010, 16:1328-1332.
18. Duric V., Banasr M., Stockmeier C.A., Simen A.A., Newton S.S., Overholser J.C., Jurjus G.J., Dieter L., Duman R.S. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int J Neuropsychopharmacol 2013, 6:69-82.
19. Dwivedi Y., Rizavi H.S., Conley R.R., Roberts R.C., Tamminga C.A., Pandey G.N. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003, 60:804-815.
20. Ferrari A.J., Charlson F.J., Norman R.E., Patten S.B., Freedman G., Murray C.J.L., Vos T., Whiteford H.A. Burden of depressive disorders by country, sex, age, and year: Findings from the Global Burden of Disease Study. PLoS Med 2013, 10:e1001547.
21. First M., Spitzer R., Gibbon M., Williams J. Structured clinical interview for the DSM-IV Axis I disorders (SCID patient edition), version 2.0 1995, New York State Psychiatric Institute, New York, NY.
22. Frank M.G., Der-Avakian A., Bland S.T., Watkins L.R., Maier S.F. Stress-induced glucocorticoids suppress the antisense molecular regulation of FGF-2 expression. Psychoneuroendocrinology 2007, 32:376-384.
23. Fujiki M., Steward O. High frequency transcranial magnetic stimulation mimics the effects of ECS in upregulating astroglial gene expression in the murine CNS. Mol Brain Res 1997, 44:301-308.
24. Gaughran F., Payne J., Sedgwick P.M., Cotter D., Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res Bull 2006, 70:221-227.
25. Goldstein B.L., Klein D.N. A review of selected candidate endophenotypes for depression. Clin Psychol Rev 2014, 34:417-427.
26. Gómez-Pinilla F., Dao L., So V. Physical exercise induces FGF-2 and its mRNA in the hippocampus. Brain Res 1997, 764:1-8.
27. González M., Cabrera-Socorro A., Pérez-García C.G., Fraser J.D., López F.J., Alonso R., Meyer G. Distribution patterns of estrogen receptor α and β in the human cortex and hippocampus during development and adulthood. J Comp Neurol 2007, 503:790-802.
28. Gos T., Schroeter M.L., Lessel W., Bernstein H.G., Dobrowolny H., Schiltz K., Bogerts B., Steiner J. S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. J Psychiatr Res 2013, 47:1694-1699.
29. Gosselin R.-D., Gibney S., O'Malley D., Dinan T.G., Cryan J.F. Region specific decrease in glial fibrillary acidic protein immunoreactivity in the brain of a rat model of depression. Neuroscience 2009, 159:915-925.
30. Gubba E.M., Fawcett J.W., Herbert J. The effects of corticosterone and dehydroepiandrosterone on neurotrophic factor mRNA expression in primary hippocampal and astrocyte cultures. Mol Brain Res 2004, 127:48-59.
31. Jans L.A.W., Riedel W.J., Markus C.R., Blokland A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry 2007, 12:522-543.
32. Jansson L., Wennström M., Johanson A., Tingström A. Glial cell activation in response to electroconvulsive seizures. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1119-1128.
33. Jorgensen P., Edgington N.P., Schneider B.L., Rupeš I., Tyers M., Futcher B. The size of the nucleus increases as yeast cells grow. Mol Biol Cell 2007, 18:3523-3532.
34. Katzenellenbogen B.S., Choi I., Delage-Mourroux R., Ediger T.R., Martini P.G., Montano M., Sun J., Weis K., Katzenellenbogen J.A. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 2000, 74:279-285.
35. Kékesi K.A., Juhász G., Simor A., Gulyássy P., Szego E.M., Hunyadi-Gulyás E., Darula Z., Medzihradszky K.F., Palkovitz M., Penke B., Czurkó A. Altered functional protein networks in the prefrontal cortex and amygdala of victims of suicide. PLoS One 2012, 7:e50532.
36. Kempton M.J., Salvador Z., Munafò M.R., Geddes J.R., Simmons A., Frangou S., Williams S.C. Structural neuroimaging studies in major depressive disorder: meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry 2011, 68:675-690.
37. Kessler R.C., McGonagle K.A., Swartz M., Blazer D.G., Nelson C.B. Sex and depression in the National Comorbidity Survey I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993, 29:85-96.
38. Khakh B.S., Sofroniew M.V. Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci 2015, 18:942-952.
39. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 2005, 10:808-819.
40. Lenth RV (2006-2009) Java applets for power and sample size [Computer software]. Retrieved 2010 Oct 28 from http://www.stat.uiowa.edu/∼rlenth/Power. http://www.stat.uiowa.edu/~rlenth/Power.
41. Li B., Zhang S., Li M., Hertz L., Peng L. Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced transactivation-mediated ERK1/2 phosphorylation. Psychopharmacology 2009, 207:1-12.
42. Little A. Treatment-resistant depression. Am Fam Physician 2009, 80:167-172.
43. Liu Q., Li B., Zhu H.Y., Wang Y.Q., Yu J., Wu G.C. Clomipramine treatment reversed the glial pathology in a chronic unpredictable stress-induced rat model of depression. Eur Neuropsychopharmacol 2009, 19:796-805.
44. Lorenzetti V., Allen N.B., Fornito A., Yücel M. Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord 2009, 117:1-17.
45. Lu Y.-P., Zeng M., Hu X.-Y., Hao X., Swaab D.F., Ravid R., Zhou J.-N. Estrogen receptor α-immunoreactive astrocytes are increased in the hippocampus in Alzheimer's disease. Exp Neurol 2003, 183:482-488.
46. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009, 15:525-539.
47. Malchow B., Strocka S., Frank F., Bernstein H.G., Steiner J., Schneider-Axmann T., Hasan A., Reich-Erkelenz D., Schmitz C., Bogerts B., Falkai P., Schmitt A. Stereological investigation of the posterior hippocampus in affective disorders. J Neural Transm (Vienna) 2015, 122:1019-1033.
48. Mateus-Pinheiro A., Patrício P., Bessa J.M., Sousa N., Pinto L. Cell genesis and dendritic plasticity: A neuroplastic pas de deux in the onset and remission from depression. Mol Psychiatry 2013, 18:748-750.
49. McKinnon M.C., Yucel K., Nazarov A., MacQueen G.M. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009, 34:41-54.
50. Miguel-Hidalgo J.J., Rajkowska G. Immunohistochemistry of neural markers for the study of the laminar architecture in celloidin sections from the human cerebral cortex. J Neurosci Methods 1999, 93:69-79.
51. Miguel-Hidalgo J.J., Baucom C., Dilley G., Overholser J.C., Meltzer H.Y., Stockmeier C.A., Rajkowska G. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 2000, 48:861-873.
52. Miguel-Hidalgo J.J., Waltzer R., Whittom A.A., Austin M.C., Rajkowska G., Stockmeier C.A. Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J Affect Disord 2010, 127:230-240.
53. Müller M.B., Lucassen P.J., Yassouridis A., Hoogendijk W.J.G., Holsboer F., Swaab D.F. Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci 2001, 14:1603-1612.
54. Nagy C., Suderman M., Yang J., Szyf M., Mechawar N., Ernst C., Turecki G. Astrocytic abnormalities and global DNA methylation patterns in depression and suicide. Mol Psychiatry 2015, 20:320-328.
55. Naninck E.F.G., Lucassen P.J., Bakker J. Sex difference in adolescent depression: do sex hormones determine vulnerability?. J Neuroendocrinol 2011, 23:383-392.
56. Nowacka M., Obuchowicz E. BDNF and VEGF in the pathogenesis of stress-induced affective diseases: an insight from experimental studies. Pharmacol Rep 2013, 65:535-546.
57. Österlund M.K., Hurd Y.L. Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog Neurobiol 2001, 64:251-267.
58. Österlund M.K. Underlying mechanisms mediating the antidepressant effects of estrogens. Biochim Biophys Acta 2010, 1800:1136-1144.
59. Ott R.L., Longnecker M. An introduction to statistical methods and data analysis 2001, Duxbury, Pacific Grove, CA. 5th ed.
60. Perera T.D., Dwork A.J., Keegan K.A., Thirumangalakudi L., Lipira C.M., Joyce N., Lange C., Higley J.D., Rosoklija G., Hen R., Sackeim H.A., Coplan J.D. Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. PLoS One 2011, 6:e17600.
61. Perez J.A., Clinton S.M., Turner C.A., Watson S.J., Akil H. A new role for FGF2 as an endogenous inhibitor of anxiety. J Neurosci 2009, 29:6379-6387.
62. Popoli M., Yan Z., McEwen B.S., Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 2011, 13:22-37.
63. Quesseveur G., David D.J., Gaillard M.C., Pla P., Wu M.V., Nguyen H.T., Nicolas V., Auregan G., David I., Dranovsky A., Hantraye P., Hen R., Gardier A.M., Déglon N., Guiard B.P. BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Transl Psychiatry 2013, 3:e253.
64. Rajkowska G., Miguel-Hidalgo J.J., Dubey P., Stockmeier C.A., Krishnan K.R. Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients. Biol Psychiatry 2005, 58:297-306.
65. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., Overholser J.C., Roth B.L., Stockmeier C.A. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
66. Rajkowska G., Stockmeier C.A. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 2013, 14:1225-1236.
67. Rodrigues S.M., LeDoux J.E., Sapolsky R.M. The influence of stress hormones on fear circuitry. Annu Rev Neurosci 2009, 32:289-313.
68. Samuels B.A., Hen R. Neurogenesis and affective disorders. Eur J Neurosci 2011, 33:1152-1159.
69. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77.
70. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
71. Schmaal L., Veltman D.J., van Erp T.G., Sämann P.G., Frodl T., Jahanshad N., Loehrer E., Tiemeier H., Hofman A., Niessen W.J., Vernooij M.W., Ikram M.A., Wittfeld K., Grabe H.J., Block A., Hegenscheid K., Völzke H., Hoehn D., Czisch M., Lagopoulos J., Hatton S.N., Hickie I.B., Goya-Maldonado R., Krämer B., Gruber O., Couvy-Duchesne B., Rentería M.E., Strike L.T., Mills N.T., de Zubicaray G.I., McMahon K.L., Medland S.E., Martin N.G., Gillespie N.A., Wright M.J., Hall G.B., MacQueen G.M., Frey E.M., Carballedo A., van Velzen L.S., van Tol M.J., van der Wee N.J., Veer I.M., Walter H., Schnell K., Schramm E., Normann C., Schoepf D., Konrad C., Zurowski B., Nickson T., McIntosh A.M., Papmeyer M., Whalley H.C., Sussmann J.E., Godlewska B.R., Cowen P.J., Fischer F.H., Rose M., Penninx B.W., Thompson P.M., Hibar D.P. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry 2015, [Epub ahead of print]. 10.1038/mp.2015.69.
72. Seeman M.V. Psychopathology in women and men: focus on female hormones. Am J Psychiatry 1997, 154:1641-1647.
73. Sheline Y.I., Wang P.W., Gado M.H., Csernansky J.G., Vannier M.W. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996, 93:3908-3913.
74. Si X., Miguel-Hidalgo J.J., O'Dwyer G., Stockmeier C.A., Rajkowska G. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology 2004, 29:2088-2096.
75. Stone D.J., Song Y., Anderson C.P., Krohn K.K., Finch C.E., Rozovsky I. Bidirectional transcription regulation of glial fibrillary acidic protein by estradiol in vivo and in vitro. Endocrinology 1998, 139:3202-3209.
76. Takahashi K., Foster J.B., Lin C.G. Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease. Cell Mol Life Sci 2015, [Epub ahead of print].
77. Torres-Platas S.G., Nagy C., Wakid M., Turecki G., Mechawar N. Glial fibrillary acidic protein is differentially expressed across cortical and subcortical regions in healthy brains and downregulated in the thalamus and caudate nucleus of depressed suicides. Mol Psychiatry 2015, [Epub ahead of print]. 10.1038/mp.2015.65.
78. Walters A.D., Bommakanti A., Cohen-Fix O. Shaping the nucleus: factors and forces. J Cell Biochem 2012, 113:2813-2821.
79. Wang Q., Van Heerikhuize J., Aronica E., Kawata M., Seress L., Joels M., Swaab D.F., Lucassen P.J. Glucocorticoid receptor protein expression in human hippocampus; stability with age. Neurobiol Aging 2013, 34:1662-1673.
80. Webster M., Witkin L.K., Cohen-Fix O. Sizing up the nucleus: Nuclear shape, size and nuclear-envelope assembly. J Cell Sci 2009, 122:1477-1486.
81. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., Charlson F.J., Norman R.E., Flaxman A.D., Johns N., Burstein R., Murray C.J.L., Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study. Lancet 2013, 382:1575-1586.
82. Willard S.L., Riddle D.R., Forbes M.E., Shively C.A. Cell number and neuropil alterations in subregions of the anterior hippocampus in a female monkey model of depression. Biol Psychiatry 2013, 74:890-897.
83. Ye Y., Wang G., Wang H., Wang X. Brain-derived neurotrophic factor (BDNF) infusion restored astrocytic plasticity in the hippocampal of a rat model of depression. Neurosci Lett 2011, 503:15-19.
84. Young E.A., Altemus M. Puberty, ovarian steroids, and stress. Ann N Y Acad Sci 2004, 1021:124-133.
85. Zarate C., Machado-Vieira R., Henter I., Ibrahim L., Diazgranados N., Salvadore G. Glutamatergic modulators: the future of treating mood disorders?. Harv Rev Psychiatry 2010, 18:293-303.
86. Zhang H., Zhao Y., Wang Z. Chronic corticosterone exposure reduces hippocampal astrocyte structural plasticity and induces hippocampal atrophy in mice. Neurosci Lett 2015, 592:76-81.
87. Zink M., Vollmayr B., Gebicke-Haerter P.J., Henn F.A. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology 2010, 58:465-473.